Cardiac toxicity in breast cancer patients treated with dual HER2 blockade. - Wikidata - wikimedia - TriplyDB

Cardiac toxicity in breast cancer patients treated with dual HER2 blockade.

Cardiac toxicity in breast cancer patients treated with dual HER2 blockade.

http://www.wikidata.org/entity/Q34694972

about

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer Getting to the Heart of the Matter: An Overview of Cardiac Toxicity Related to Cancer Therapy The prevention, detection and management of cancer treatment-induced cardiotoxicity: a meta-review Twenty years of anti-HER2 therapy-associated cardiotoxicity Cardiac risk in the treatment of breast cancer: assessment and management.Pertuzumab in Combination with Trastuzumab and Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Safety, Efficacy, and Progression Free Survival.Effect and safety of dual anti-human epidermal growth factor receptor 2 therapy compared to monotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: a systematic review.An update on cardio-oncology.The expanding role of pertuzumab in the treatment of HER2-positive breast cancer Does dual HER-2 blockade treatment increase the risk of severe toxicities of special interests in breast cancer patients: A meta-analysis of randomized controlled trials.Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?Infection risk in breast cancer patients treated with trastuzumab: a systematic review and meta-analysis.Pertuzumab for the treatment of breast cancer: a safety review.Cardiotoxicity of ErbB2-targeted therapies and its impact on drug development, a spotlight on trastuzumab.

P2860

Q26785612-D42E8F50-FCC9-4719-99D7-FD719F3DB60D Q26797138-EC499EB2-A975-42E3-8D5B-AB3BC495A229 Q27010466-D4388526-4C2F-4A5E-8A09-D325A3FC4640 Q28079391-C3C80F61-E9E0-4F6F-BA52-8A66578381FE Q28081385-87D72D34-D7AF-4B76-AC63-1CA48F5060DA Q33618685-880B09D9-739E-49EC-BD47-3FCDF755E6EE Q34169075-4AC226B0-64B8-4FCE-B534-68C52FB69C3D Q34650059-F6CA2246-855F-4E52-923B-970F7853EA86 Q35653163-E4D507AD-9064-40ED-88AF-8D2C85115CFC Q36281513-915BE5E2-666D-4007-8BEA-0DCB156144B9 Q37131070-315DA609-192B-429C-A49E-98D6DB6F283B Q38266772-D2E158E5-4320-48FB-A1FC-FA6CAA9A07A2 Q38776876-5EEE0BC6-0AC1-437E-8156-DD99140CE1AF Q39344380-7F7D3DD6-FA80-4F23-8069-3453ED8A2B5D

P2860

Cardiac toxicity in breast cancer patients treated with dual HER2 blockade.

http://www.wikidata.org/entity/Q34694972

description

2013 nî lūn-bûn

@nan

2013 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Cardiac toxicity in breast cancer patients treated with dual HER2 blockade.

@ast

Cardiac toxicity in breast cancer patients treated with dual HER2 blockade.

@en

Cardiac toxicity in breast cancer patients treated with dual HER2 blockade.

@nl

type

label

Cardiac toxicity in breast cancer patients treated with dual HER2 blockade.

@ast

Cardiac toxicity in breast cancer patients treated with dual HER2 blockade.

@en

Cardiac toxicity in breast cancer patients treated with dual HER2 blockade.

@nl

prefLabel

Cardiac toxicity in breast cancer patients treated with dual HER2 blockade.

@ast

Cardiac toxicity in breast cancer patients treated with dual HER2 blockade.

@en

Cardiac toxicity in breast cancer patients treated with dual HER2 blockade.

@nl

P1433

Q34694972-997EDC36-555A-45A4-B60D-7B21B56F3033

P1476

Q34694972-12506C09-D665-4F8D-BD13-E66884D55D7C

P2093

Q34694972-2512529D-6B9C-4244-A200-1F604CBC4797

Q34694972-6DF9050A-C50D-4FFE-82BA-F50B23A99188

Q34694972-72F72AA3-EEAD-45C1-9D00-25D9C3506ECE

Q34694972-9783A2A3-2BC7-40D0-9810-43B87E1A2E1D

P2860

Q34694972-1C807FA8-9C56-453F-AB53-7558B35C40F2

Q34694972-1FDC61E3-12F7-45B8-AA66-5F9079AED49D

Q34694972-235F4346-D8BE-4EB2-B680-472EEE71B744

Q34694972-273117CB-5E4B-4AA5-879A-B5EB28337C30

Q34694972-3E8F72D1-1F04-4AF8-8E87-8DDE48111F01

Q34694972-51745768-D674-4831-97B0-86D139EFDF67

Q34694972-57EE2528-1AE8-440C-A982-B301D668B4B8

Q34694972-5967E579-3303-432C-A5AB-01C5B5978B8A

Q34694972-804C6EDB-537A-4D78-B44E-C21AC87C7FCB

Q34694972-814AA026-97CE-47E8-B157-14C25CA485AE

P304

Q34694972-8A8F3BC1-4697-4165-B7D7-F779EEAC804E

P31

Q34694972-06291F45-8AB9-481D-904D-A82733E1EA77

Q34694972-3c06f791-85dc-424a-bb86-1cdebf2d6e78

P356

Q34694972-53B0FE65-1AAA-40C2-9579-0CA785CD4FB0

P433

Q34694972-B31CC569-888B-4591-AD1A-D505F35A20BF

P478

Q34694972-61AD98EF-7DBF-487D-9E63-842D3CFF73BD

P577

Q34694972-C0EE72AC-1AF2-417A-A879-D3C89CA56A66

P698

Q34694972-6296314D-5CAD-4D2F-B912-E8E7225F2E86

P356

P1433

International Journal of Cancer

P1476

Cardiac toxicity in breast cancer patients treated with dual HER2 blockade.

@en

P2093

Andreas Nearchou

http://www.w3.org/2001/XMLSchema#string

Antonis Valachis

http://www.w3.org/2001/XMLSchema#string

Nikolaos P Polyzos

http://www.w3.org/2001/XMLSchema#string

Pehr Lind

http://www.w3.org/2001/XMLSchema#string

P2860

Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

Cardiac dysfunction in the trastuzumab clinical trials experience

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

P304

2245-2252

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.28234

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

133

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23629633

http://www.w3.org/2001/XMLSchema#string